Biocept Presentation at Molecular Medicine Tri-Con Meeting Highlights Potential of CNSide™ Assay to Support Development of Targeted Therapies for Metastatic Brain Cancer
22 Fevereiro 2022 - 6:17PM
Business Wire
Ability to serially monitor treatment response,
identify key biomarkers and customize assay aids clinical research
efforts to improve treatment for metastatic cancers involving brain
and spinal cord
Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular
diagnostic assays, products and services, highlighted the ability
of its CNSide™ cerebrospinal fluid (CSF) assay to aid in
therapeutic research programs for metastatic brain cancer in a
presentation at the Molecular & Precision Med Tri-Con meeting.
The company is also exhibiting (booth #508) at the conference,
which is the leading international meeting for the precision
medicine community, Feb. 21-23, 2022, in San Diego.
During the presentation, Michael Dugan, M.D., Biocept’s Chief
Medical Officer and Medical Director, discussed the growing
interest in improving the diagnosis and treatment of leptomeningeal
disease (LMD), a devastating complication in which metastatic
cancer spreads to the membrane surrounding the brain and spinal
cord. Newer targeted therapies can often reduce or resolve
debilitating symptoms of LMD and extend life expectancy. However,
the current standards of care, CSF cytology and radiological
imaging, have limited sensitivity for detecting central nervous
system metastasis, and do not identify molecular treatment targets
or quantify tumor cell counts.
“A key to precision medicine is identifying molecular targets
for therapy,” Dr. Dugan said. “Relying on the primary tumor is not
sufficient because biomarker status often differs between the
primary and metastatic tumors. With CNSide, we have the first
commercially available method to measure biomarker status in
real-time during therapy and quantify changes in tumor cell counts
to really understand how patients are responding to therapy—as
opposed to waiting months for radiologic changes or another
surgical biopsy.”
“Companies developing novel therapies for metastatic brain
cancers face significant challenges in determining treatment
response with traditional methods,” said Samuel D. Riccitelli,
Biocept’s Chairman, and Interim President and CEO. “We believe that
serial quantitative monitoring with our CNSide assay can have a
tremendous impact on the success of many therapeutic clinical
trials, and we are pleased to support these important research
efforts aimed at providing new treatments for patients with limited
time and options.”
CNSide is based on Biocept’s proprietary quantitative tumor cell
capture and detection method, paired with assays to identify
actionable molecular treatment targets. The assay answers three key
questions that may help inform treatment decisions: Is there tumor?
Is there a target for treatment? Is there a trend to treatment
response? Because genetic changes can occur as metastatic cancer
spreads to the central nervous system, the evaluation of
cerebrospinal fluid provides a unique opportunity to identify
biomarkers such as HER2 and EGFR in patients with metastatic
breast, lung, and other cancers, to help guide therapy selection.
In addition, the quantitative tumor cell count assay can be used in
a serial fashion to more effectively monitor the response to
therapy than other current methods.
A recording of the presentation, titled “A Novel CSF Assay to
Help Diagnose, Manage, and Follow Response to Therapy in Patients
with Leptomeningeal Metastasis,” will be available on the Biocept
website after the conference concludes.
About Biocept
Biocept, Inc. develops and commercializes molecular diagnostic
assays that provide physicians with clinically actionable
information for treating and monitoring patients diagnosed with a
variety of cancers. In addition to its broad portfolio of
blood-based liquid biopsy assays, Biocept has developed the CNSide™
cerebrospinal fluid assay that detects cancer that has metastasized
to the central nervous system. Biocept’s patented Target Selector™
technology captures and quantitatively analyzes cerebrospinal fluid
tumor cells for tumor-associated molecular markers, using
technology first developed for use in blood. Biocept also is
leveraging its molecular diagnostic capabilities to offer
nationwide COVID-19 RT-PCR testing to support public health efforts
during this unprecedented pandemic. For more information, visit
www.biocept.com. Follow Biocept on Facebook, LinkedIn and
Twitter.
Forward-Looking Statements Disclaimer
This news release contains forward-looking statements that are
based upon current expectations or beliefs, as well as a number of
assumptions about future events. Although we believe that the
expectations reflected in the forward-looking statements and the
assumptions upon which they are based are reasonable, we can give
no assurance that such expectations and assumptions will prove to
be correct. Forward-looking statements are generally identifiable
by the use of words like "may," "will," "should," "could,"
"expect," "anticipate," "estimate," "believe," "intend" or
"project," or the negative of these words or other variations on
these words or comparable terminology. To the extent that
statements in this news release are not strictly historical,
including, without limitation, statements as to the ability of
CNSide to impact life expectancy and quality of life, our ability
to establish CNSide as the new standard of care for the diagnosis
of patients with suspected cancer metastasis to the CNS, our
ability to expand our CSF testing menu for additional tumor types
and biomarkers in the future, and our ability to provide physicians
with clinically actionable information for treating and monitoring
patients diagnosed with a variety of cancers, such statements are
forward-looking, and are made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995.
The reader is cautioned not to put undue reliance on these
forward-looking statements, as these statements are subject to
numerous risk factors as set forth in our Securities and Exchange
Commission (SEC) filings. The effects of such risks and
uncertainties could cause actual results to differ materially from
the forward-looking statements contained in this news release. We
do not plan to update any such forward-looking statements and
expressly disclaim any duty to update the information contained in
this press release except as required by law. Readers are advised
to review our filings with the SEC at http://www.sec.gov/.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220222006100/en/
Media Contact: Andrea Sampson, Sampson PR Group
asampson@sampsonprgroup.com, 562-304-0301
Investor Contact: Jody Cain, LHA Investor Relations
Jcain@lhai.com, 310-691-7100
Biocept (NASDAQ:BIOC)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Biocept (NASDAQ:BIOC)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024